🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
10.01
-0.18 (-1.77%)
Nov 19, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Soquelitinib’s Phase I atopic dermatitis data showed EASI-75 of 75% in the higher-dose cohort, durable responses and a favorable safety profile. Key 2027 catalysts include PTCL analyses, HS data, asthma trial initiation and Phase II AD results.

Operator

Welcome to the Jefferies 2026 Healthcare Conference. Please welcome Jeff Arcara, Chief Business Officer at Corvus.

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

Thank you. Thank you. My name is Jeff Arcara. I am the Chief Business Officer for Corvus Pharmaceuticals. This afternoon, we will spend a few minutes providing an overview of Corvus as well as our pipeline, and we will focus specifically on soquelitinib, which is our novel oral highly selective ITK inhibitor. We will also review some of our clinical data as well as some of the key clinical data readouts that we will see starting in Q1 2027 and throughout the entire year. This is our forward-looking statement. You can review this statement along with our slides on our investor website. First, who is Corvus? We are a clinical-stage company developing novel immune modulators for the treatment of cancer and immune diseases.

We have our lead program, soquelitinib, which is in a phase III registrational trial for peripheral T-cell lymphoma, which is a really tough cancer to treat, as well as a phase II program in moderate to severe atopic dermatitis. That is called the SIERRA1 trial, and both those trials are enrolling. Soquelitinib represents a pipeline and a product opportunity for us, so we have a number of additional clinical trials that we are running, including HS, which just started enrolling last month, as well as we are going to start an asthma study in the beginning of 2027. ITK is a platform technology for us. We have a number of next-generation and backup compounds in development, and we have strong IP protection through November of 2037, and that is 2042 if you include pharmaceutical extensions.

Finally, on the bottom of the slide, you can see we have a Chinese partner, Angel Pharmaceuticals, who we own 49% of, and they are running clinical trials with soquelitinib in China as well, including an AD study, which we will talk about in a few slides. First, why ITK? ITK stands for interleukin-2-inducible T-cell kinase. It is involved in T-cell receptor signaling and differentiation. If you look at the left-hand side of the slide, you can see naive CD4 T- cells can differentiate into Th1, Th2, or Th17 cells. If you look at the right-hand side of the slide, essentially how soquelitinib works is that we block Th2 and Th17 and their respective cytokines. So think IL-4, 5, and 13, like Dupixent. Think IL-17, like Bimzelx.

What that does is that skews the immune response towards the Th1 cells, which are involved in fighting cancer and viral elimination. It is also important to note, if you look at the upper right-hand side of the slide, we are very selective for ITK, but we spare RLK. RLK stands for resting lymphocyte kinase. It is a redundant T-cell signaling pathway, and by sparing that, we help preserve the Th1 response. If you look at the lower right hand of the slide, in addition to us blocking Th17 and IL-17, we have shown that we can shift or switch Th17 cells to become active Treg cells. In essence, we are taking the foot off the gas by lowering the cytokines, and we are putting the foot on the brake at the same time by increasing Tregs. We are modulating or rebalancing the immune system. We are not suppressing it.

How do we accomplish that? We accomplish that through some really smart science and making a very targeted and selective drug. As you can see in the center of that slide, you can see the kinome tree showing specific for ITK. If you look at the upper left-hand corner of that slide, that is a specific binding table. KD, the lower the KD, the more strong the binding. The first row, ITK, 6.5. Very strong binding for ITK. If you look at the very bottom, RLK, 2700. So we are highly selective for ITK over RLK, as well as other TEC family kinases. That is important not only for efficacy, but also for safety. Why do I say that? ITK has very limited tissue distribution. It is found primarily on NK cells and T- cells. You can see we are very selective just for ITK.

With that, we expect limited off-target effects because of that, and that has actually played out in our clinical data. We have seen a very good safety profile comparable to placebo. How does this compare to currently approved therapeutic agents? Because we work more upstream, blocking Th2 and Th17, you can see in that first row, the green across, we block a broader set of cytokines. This does two things for us. It allows us to treat a broader set of patients. For example, patients that may have failed prior therapies or patients that have a disease that involves both Th2 and Th17. Think atopic dermatitis, think asthma. It also allows us to treat a broader set of patients, or excuse me, a broader set of diseases. In addition to Th2 and Th17-driven diseases, we believe we can treat IL-5-driven diseases as well as fibrotic diseases.

We actually have preclinical data models in atopic dermatitis, asthma, psoriasis, systemic sclerosis, IPF, and colitis models, and others. There is a lot more we can do with soquelitinib, but also with our next-generation ITK inhibitors. When you look at all these diseases together, they make up a very significant targeted addressable market, 130 million patients across the G7. About 20 million of those would be our more severe, moderate to severe patients that we would treat. On the right-hand side, you can see that market is projected to be $170 billion, with just a fraction of that being orals, only 10%. A significant opportunity for a novel, safe oral therapy in I&I diseases. Let us take a closer look at our pipeline and what is the clinical data that is going to drive our readouts in 2027.

At the top of the slide, I mentioned we have a phase III trial in peripheral T-cell lymphoma. That is actually in relapsed and refractory PTCL. That is a really tough disease to treat. Our current standard of care is inadequate. It is not tolerated very well. It does not work very well. NCCN guidelines actually recommend a clinical trial in place of those drugs currently. So, significant unmet need for us to fill. You can see in that center column, we have a futility analysis that will be happening in Q1 2027. We also have orphan drug designation and fast track designation. In terms of phase II trials, we have the atopic dermatitis trial, that is the SIERRA1 trial. That will read out in Q3 of 2027. And then we also will be starting an asthma trial that will start in Q1.

Because of the mechanism of action that we just talked about, we are going to actually enroll both T2 and non-T2 asthma patients, because we can block both Th2 and Th17. What we will do is that we will have an interim analysis, and we will look at each of those groups separately, and if we see a non-performing group, we will drop them from the trial so we can continue the trial to keep going. In terms of phase I in the middle, you can see we have an HS study that just started. That is a Th17-driven disease, right? You look at Bimzelx, which blocks IL-17A and IL-17F. This is the first time we are going into a Th17 disease in HS, so we have designed this as a true proof of concept study, but it will read out relatively quickly in the first half of 2027.

And at the bottom, Angel, our partner in China, will look more into the study. They have their first cohort done and enrolled, and that data will read out in March of 2027. The second cohort will start enrolling now in November, and that data should be available in the second half of 2027. Speaking of AD, let us look at the clinical data a little closer. So this is our phase I trial design. Just to base set everyone, there was a total of 72 patients with moderate to severe atopic dermatitis, 48 on drug, 24 on placebo. We did four cohorts. Cohorts one and two are the low-dose cohorts. They were randomized 3:1, so 12 on drug, four on placebo. These were four weeks of treatment, and it was a QD versus BID. Cohorts three and four are our higher dose.

That is four weeks of treatment and eight weeks of treatment respectively, for again, a total of 72 patients. If you look at the study design on the right, it is pretty standard. Its safety is the primary endpoint, but we also looked at change in EASI score, EASI-75, 90, and IGA 0/1. It is also important to note there were no concomitant steroids, so this is monotherapy data that we are showing. So what did the trial show? We saw that with increasing the dose and increasing the duration, we saw deeper responses and more durable responses. So on the left-hand side is our first three cohorts. That was, again, four weeks of data. Really, the focus is on the right-hand side. That is our cohort four data. Again, that was eight weeks of data of treatment. It is the higher dose.

If you look at that blue bar, that is EASI-75. We saw a 75% response rate versus placebo at 20. That's actually comparable to a JAK level of efficacy. If you look at the right-hand side, the light blue bar, 33%, that's IGA 0/1. That's actually comparable to a biologic level. Right now, we're sitting somewhere between a biologic and a JAK in terms of level of efficacy. Again, that's for cohort four. If you look at all of the patients together, on the left-hand side, you can see the orange line is the placebo, cohorts one through four. The blue line is the active group, soquelitinib. You can see a significant separation from placebo starting as early as two weeks. On the right-hand side, as a reminder, we had 35% of our patients having a prior systemic therapy. That's what you're seeing on the right side. It works.

Soquelitinib worked just as well, but what happened is you can see placebo does not work as well, what you would expect in terms of treating sicker patients. Both of those are statistically significant separations from placebo. We also looked at true treatment-resistant patients. We did case studies. We found six patients in total in cohorts three and four that actually were resistant to drugs like Dupixent or Rinvoq, even OX40 that is no longer with us. The four patients with soquelitinib, three of the four responded to therapy, as you can see on the right-hand side, and the two placebos actually flared. In addition to looking at response, we also looked at durability of treatment. What you can see on the left-hand side is the first three cohorts, EASI-75, just under 40%. In the gray box, that's off of treatment.

90 days off of treatment, we saw that the response was still at the same level. On the right-hand side is cohort four. Again, that was a 75% response. In the gray box, you can see 30 days off of therapy, they maintain their level of response. This is interesting for us to look at and think about. This is where the Treg story starts to come into play if we can create more of a durable response by increasing Tregs. We're going to look at this more deeply in our phase II SIERRA1 trial. We have a 90-day follow-up period. We're not the only ones that looked at this. The JAKs and the biologics looked at this as well, and you can see on this slide, essentially after stopping treatment with JAKs or a biologic, patients rebounded as quickly as one week.

In addition to the clinical data, we also looked at biomarker data and see a consistent effect on Th2 immunology. On the left-hand side, you can see a dose response reduction in Th2 cells. In the center panel and right panel are cohorts three and four. We saw a reduction in IL-4, IL-5, IL-13, and TARC, and it's both on therapy and in the gray box off therapy, we saw a reduction. As I mentioned, Tregs, we actually looked at Tregs and saw we had persistent increase in Tregs in both on treatment and off treatment. If you look at the upper row, that's 20 days on treatment, 28 days on treatment, cohorts three, cohorts four, and combined. The bottom row is 30 days off of treatment.

If you look at the lower right-hand box there, you can see we actually had a significant separation from placebo in terms of increased Tregs out to 30 days. As important as efficacy is, safety is probably even more important in terms of atopic dermatitis. You are treating 18-year-olds with eczema. Overall, we have a very good safety profile with soquelitinib to date. You can see pretty much comparable to placebo, even if you look at grade 3, serious AEs, or any AEs leading to discontinuation of the drug. Excuse me. In summary, for the AD data, we saw positive clinical results. We saw EASI-75 in terms of response rates. We also saw a very favorable safety profile. We saw deeper and durable responses, including no rebound.

We have seen response in challenging patients, like those that have failed therapies, and we have seen supportive biomarker data that supports immune rebalancing. In the last few minutes, let us just review some of the current studies we have underway. This is our phase II trial called SIERRA1. It is 12 weeks of treatment with 90-day follow-up. You can see on the left-hand side, it is moderate to severe, greater 18 years of age. Excuse me. Thank you. Moderate to severe AD, greater of 18 years of age. EASI score of greater than 16. Excuse me. Travel is hard. I do not know. I just lost my voice. There are two slides left. Do you want to, let us see if I can get through it. I cannot. You want to just clear these last two slides?

Zack Kubow
VP of Investor Relations and Corporate Communications, Corvus Pharmaceuticals

Sure.

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

Okay. I apologize.

Zack Kubow
VP of Investor Relations and Corporate Communications, Corvus Pharmaceuticals

No problem. Hey, everyone. Zack Kubow, Investor Relations. This slide shows the SIERRA1 phase II AD trial that is enrolling now. You can see that we are looking at four cohorts of 50 patients each, 200 milligrams QD, 200 milligrams BID, and 400 milligrams QD versus placebo. We are planning to announce results for this in Q3 of 2027. Our partner in China, Angel Pharma, is also running a clinical trial in atopic dermatitis, and that is a phase I-B, phase II trial. The first phase I-B portion is enrolling now. Cohort one has completed enrollment. We expect to announce data from that in March of 2027. We have announced that the baseline characteristics from that patient group of 24 patients is similar to the baseline characteristics of our own phase I trial that we just showed data from.

We anticipate that they will start enrolling cohort two of that trial in late November of this year, with that data coming in the second half of 2027. After the phase I-B portion, they can choose to extend the trial into 60 to 90 additional patients at a dose that they select based on the results of the phase I-B. In the end of September, we announced the initiation of a hidradenitis suppurativa phase I-B trial. This is a proof-of-concept trial in HS, which is a Th17 disease, so it is the first time we are going to be looking at a Th17-specific disease. It is a 12-week trial enrolling up to 25 patients. It is open label, no placebo. We are looking at safety and then efficacy endpoints, HiSCR and IHS4 at 12 weeks.

We will also be looking at skin and blood biomarkers to measure that impact on IL-17. In conclusion here, this is our exciting 2027 value-driving milestone path. We will start with the initiation of an asthma trial in early Q1. We will have a PTCL futility analysis for the phase III trial in Q1. In March 2027, we have the phase I-B cohort one top- line. In the second quarter, our partner Angel will be initiating their own asthma trial. The HS data we expect to have in the first half of 2027. After that, we expect to have the SIERRA1 phase II atopic dermatitis trial data in Q3 2027. The Angel cohort two data will come in the second half of the year. The PTCL phase III top- line data by year-end 2027. An exciting year that we are looking forward to reporting out.

With that is our last slide.

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

Thank you, Zack.

Zack Kubow
VP of Investor Relations and Corporate Communications, Corvus Pharmaceuticals

You okay?

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

I'm okay, I think.

Zack Kubow
VP of Investor Relations and Corporate Communications, Corvus Pharmaceuticals

Are we doing I don't think we're doing Q&A, right?

Speaker 4

No, I think we're done.

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

What time? How much time do we have?

Speaker 4

You still got five minutes.

Zack Kubow
VP of Investor Relations and Corporate Communications, Corvus Pharmaceuticals

Do you want to do

Speaker 4

We can do it.

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

Okay, we have time. The best we can.

Speaker 5

How big is the PTCL market?

Jeff Arcara
Chief Business Officer, Corvus Pharmaceuticals

How big is the PTCL market? It is about 70,000 prevalence globally, 10,000 in the U.S., 15,000 in Europe, and about 30,000 rest of world. U.S. market incidence is about 3,300 patients. No questions? Thank you for your time.